2,0
6. Apr. 2015
Aktueller Mitarbeiter, mehr als 10 Jahre
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Leader within the industry, strong product pipeline and product portfolio. Company continues to invest in the future and positioned for longterm success. Poised to maintain market share lead or close second, depending on product and category.
Kontras
Core culture of what has made Alcon a great place to work has evaporated after the acquisition by Novartis. Company looses focus on long term strategy in lieu of quarterly targets. Company is not equipped to effectively handle current medical rules and regulations versus the competition. There is no culture of accountability. Management does not display a clear path to success, it is overshadowed by short term goals to satisfy next tier management.